Verve Therapeutics Ownership
| VERV Stock | USD 6.31 0.14 2.17% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Verve |
Verve Stock Ownership Analysis
About 94.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.08. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Verve Therapeutics recorded a loss per share of 2.46. The entity had not issued any dividends in recent years. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Verve Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people. For more information please call Sekar MD at 617 603 0070 or visit https://www.vervetx.com.Besides selling stocks to institutional investors, Verve Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Verve Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Verve Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Verve Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Verve Therapeutics Insider Trades History
About 5.0% of Verve Therapeutics are currently held by insiders. Unlike Verve Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Verve Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Verve Therapeutics' insider trades
Verve Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Verve Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verve Therapeutics backward and forwards among themselves. Verve Therapeutics' institutional investor refers to the entity that pools money to purchase Verve Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Arch Venture Corp | 2024-12-31 | 2 M | Jacobs Levy Equity Management, Inc. | 1.8 M | Baker Bros Advisors Lp | 2024-12-31 | 1.7 M | Nuveen Asset Management, Llc | 2024-09-30 | 1.7 M | Geode Capital Management, Llc | 2024-12-31 | 1.6 M | Fmr Inc | 2024-12-31 | 1.4 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.4 M | Redmile Group, Llc | 2024-12-31 | 1.3 M | Ecor1 Capital, Llc | 2024-12-31 | 1.2 M | Alphabet Inc | 2024-12-31 | 12.3 M | Blackrock Inc | 2024-12-31 | 7.5 M |
Verve Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verve Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verve Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Verve Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Verve Therapeutics Outstanding Bonds
Verve Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Verve Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Verve bonds can be classified according to their maturity, which is the date when Verve Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| VERTICAL HOLDCO GMBH Corp BondUS92537VAA89 | View | |
| VERTICAL U S Corp BondUS92537RAA77 | View | |
| US92535UAB08 Corp BondUS92535UAB08 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Verve Therapeutics Corporate Filings
| 5th of February 2025 Other Reports | ViewVerify | |
| 31st of January 2025 Other Reports | ViewVerify | |
F4 | 10th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 18th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.